Introduction: Follicle stimulating hormone receptors (FSHR) are well known to be expressed in gonads and in gonadal tumours. Recently, their incidence has also been revealed in endocrine non-gonadal tumours such as adrenal and pituitary tumours. Moreover, FSHR immunostaining has also been reported in endothelium of intra-and peritumoral blood vessels of a large series of cancers. The present paper reports on the incidence of FSHR in both tumoral cells and some intratumoral blood vessels of neuroendocrine tumours (NETs). Material and methods: Sixteen NETs samples were taken from 14 patients. The tumour samples were immunostained using the antibody raised against 1-190 amino acid sequence from the human FSH-R and anti-Ki67 antibody. Results: In all the samples examined, the majority of tumoral cells were immunostained with anti-FSHR antibody. Positive immunostaining concerned also the intratumoral blood vessels endothelia in a half of the examined samples. Immunopositive blood vessels were found more often in tumours with higher Ki-67 index. 
Introduction
Follicle stimulating hormone receptors (FSHR) are well known to be expressed in gonads and in gonadal tumours [1] . However, their incidence was also recently revealed in numerous non-gonadal tumours. Radu et al. [2] found the expression of FSHR in endothelia of intra-and peritumoral blood vessels in a large series of non-gonadal cancers (prostate, breast, colon, pancreas, bladder, kidney, lung, liver and stomach). The quoted authors claim that FSHR incidence is specific for tumoral and peritumoral blood vessels since they found them neither in endothelia of non-tumoral vessels nor in tumoral cells. In our earlier study, we showed that FSHR could be detected immunohistochemically in both endothelia and tumoral cells in non-gonadal endocrine tumours: pituitary adenomas, adrenocortical tumours and pheochromocytomas [3] . Recently the presence of FSHR has been also reported in pancreatic neuroendocrine tumours [4] . Simultaneously, a similar preliminary observation concerning NETs of different origin, was done by us [5] .
The present paper reports on the incidence of FSHR in both tumoral cells and some intratumoral blood vessels of neuroendocrine tumours. 
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Material and methods
Sixteen NETs samples were taken from 14 patients. The samples concerned five bronchial 'carcinoids', seven intestinal 'carcinoids', three metastases to the liver and one neuroendocrine pancreatic cancer. Paraffin sections of the tumour samples were immunostained using the rabbit polyclonal antibody raised against 1-190 amino acid sequence from the human FSH-R (sc-13935) purchased from Santa Cruz Biotechnology Inc. (Santa Cruz Biotechnology, CA, USA), applied in a working dilution of 1:100. Additionally, the sections were immunostained with anti-Ki-67 (MIB-1) monoclonal antibody (Dako Cytomation, Glostrup, Denmark). The visualisation of the primary antibodies was done by means either of the REAL EnVision Detection System (FSHR) or the StreptABComplex/ /HRP Duet (Ki 67), both purchased from Dako Cytomation. The intensity of immunostaining in the tumoral cell cytoplasm was scored semiquantitatively using a descriptive scale: negative staining (score = 0), weak staining (score = 1), moderate staining (score = 2) and strong staining (score = 3). For a negative control, the primary antibody was omitted in the immunostaining procedure. For a positive control, a sample of the human testis was used. This study was approved by the Local Bioethical Committee, decision number RNN/537/11/KB dated 14 June, 2011.
Results
In all the samples examined, the majority of tumoral cells were immunostained with anti-FSHR antibody ( Fig. 1 and  2) . Positive immunostaining concerned also the intratumoral blood vessels endothelia in 8/16 examined samples ( Fig. 3 and 4) . When we compared NETs samples according to Ki-67 values, there was no evident difference in FSHR immunostaining scores in tumoral cells. The mean score calculated in NET samples with Ki-67 index ≥ 2% was 1.8 ± 0.2 (means ± SEM) and in the samples with Ki-67 < 2% it was 1.5 ± 0.3 (means ± SEM). On the other hand, immunopositive blood vessels were found more often in the tumours with higher Ki-67 index (5/6 with Ki-67 ≥ 2% and 2/9 with Ki-67 < 2%).
Discussion
The observations presented above corroborate the data of Sardella et al. [4] showing that FSHR are expressed in tumoral cells of NETs. The quoted authors showed that FSHR co-localise with chromogranin A, a marker of tumoral cells, but not with von Willebrand's factor, which is a marker of vascular endothelia. However, in contrast to the cited data, our finding shows that FSHR were localised not only in the tumoral cells, but in some cases in blood vessels as well. This observation, in turn, is in agreement with the earlier data of Radu et al. [2] who demonstrated the FSHR immunopositivity of vascular endothelia in the intraand peritumoral blood vessels of different cancers. However, it must be underlined that the endothelial immunostaining in NETs in our study occurred only in a half of the samples examined by us, and is rather rare in tumours with lower grade of differentiation. We did not observe the differences depending on the origin of NETs, however, our material was too small to allow a definitive conclusion.
The question arises whether the ectopic expression of FSHR in NETs have any consequences for the clinical outcome of the tumour. The functionality of these receptors remains unknown and needs further study. It is known that the ovary stimulation of FSHR by FSH leads to the enhanced proliferation of granulosa cells, increased secretion of vascular endothelial growth factor (VEGF), and increased angiogenesis [6] . A similar observation was made with ovarian cancer cells SK-OV-3 [6] . FSH also inhibits ovarian cancer cell apoptosis by up-regulating survivin and downregulating programmed cell death gene 6 (PDCD6) and death receptor 5 (DR5) [7, 8] .
Summing up, FSHR, if they are functional, may mediate the signals which can enhance further tumour growth.
